STUDIO

BioStock Investor Meeting: Interview with Cereno Scientific

BioStock Investor Meeting: Interview with Cereno Scientific

Biotech Cereno Scientific develops new treatments for cardiovascular disease, the most common cause of death worldwide. The company's lead candidate CS1 targets the rare...

RECOMMENDED READING

BioStock Investor Meeting: Interview with Cereno Scientific

BioStock Investor Meeting: Interview with Cereno Scientific

Biotech Cereno Scientific develops new treatments for cardiovascular disease, the most common cause of...
Aptahem

Aptahem on the application to initiate clinical studies

Aptahem has submitted applications to the regulatory authorities and to the Central Ethics Committee...

EVENT